This article is more than 5 years old. Information may no longer be current.
Array BioPharma, Bristol-Myers Squibb to collaborate on colorectal cancer study
Click Here to Manage Email Alerts
Array BioPharma and Bristol-Myers Squibb entered a clinical collaboration to investigate two combinations as potential treatment for patients with metastatic colorectal cancer who have microsatellite stable tumors.
A phase 1/phase 2 study will be designed to establish recommended doses and explore preliminary antitumor activity of the MEK inhibitor binimetinib (MEK162, Array BioPharma) plus the anti–PD-1 monoclonal antibody nivolumab (Opdivo, Bristol-Myers Squibb).
The trial — expected to begin in the second half of this year — also will evaluate binimetinib in combination with nivolumab and the CTLA-4 immune checkpoint inhibitor ipilimumab (Yervoy, Bristol-Myers Squibb).
“Array is pleased to announce this new collaboration with Bristol-Myers Squibb,” Ron Squarer, CEO of Array BioPharma, said in a press release. “Based on emerging data, we believe that studying combinations of targeted therapies — such as binimetinib — with immuno-oncology agents, such as Opdivo and Yervoy, could provide important scientific advances for patients fighting cancer.”
Trial results will be used to determine optimal approaches to further clinical development of these combinations.
“Colorectal cancer remains a challenging tumor where immunotherapy benefits have been limited to a subset of patients,” Fouad Namouni, senior vice president and head of oncology development at Bristol-Myers Squibb, said in the release. “We are committed to investigating a wide range of oncology therapies, and look forward to studying the combination of Array’s MEK inhibitor and our immunotherapies with the goal of developing more treatment options for patients.”